Sustained Release Excipients Market To Reach $2.36 Billion By 2030

Sustained Release Excipients Market Growth & Trends

The global sustained release excipients market size is expected to reach USD 2.36 billion by 2030, expanding at a CAGR of 8.4% from 2023 to 2030, according to a new report by Grand View Research, Inc. The growth of the sustained-release excipients market is attributable to the growing demand for sustained-release drugs, the improvement in patient compliance rate, and the multiple advantages of this drug-delivery method over conventional methods. These excipients are usually used as capsules and tablet formulations to release the drug slower; thereby, the drug has to be taken at less frequent intervals making it advantageous over immediate-release formulations. The sustained release of excipients' disintegration, dissolution, or degradation leads to the modified slower drug release.

Reduced dosage frequency, improved patient compliance, maintenance of the constant level of drug in blood plasma, lower instances of toxicity due to overdose, and higher cost-effectiveness, in the long run, are some of the major advantages of using sustained release drug delivery systems. Regular consumption of oral conventional drugs generally results in undesired symptoms, such as gastrointestinal upset, cramps, nausea, and diarrhea. The use of sustained release drug formulations provides patients relief from these symptoms and helps maintain desired therapeutic drug levels in the body. Moreover, these have been increasing the adoption of sustained-release formulations, enabling higher patient compliance and improved therapeutic effect.

Over the past few years, there has been a global rise in antibiotic resistance. Overuse and misuse of conventional drug formulations have been identified as the major cause of antibiotic resistance. In some instances, patients recover within a few days of drug administration and discontinue the recommended dose of drugs, culminating in resistance. Such resistance leads to higher medical costs, longer hospital stays, and a rise in mortality rate. The rise in the incidence of infectious and chronic diseases has also resulted in antibiotic resistance, which has negatively impacted the conventional dosage forms market. Thus, alternative procedures to treat and manage these diseases are being implemented.

Controlled release formulations have been extensively accepted among physicians to prevent antibiotic resistance. Since these formulations generate preferred therapeutic drug levels in blood plasma and decrease the dosage frequency, they are an ideal choice among physicians, increasing their demand in the industry. The impact of disruptions on pharmaceutical production and subsequently on excipient demand affected by lockdowns and transport and travel bans across several countries due to the COVID-19 pandemic will be comparatively short-term. However, the supply disruptions due to extended lockdowns in different countries may substantially impact the oral solid dosage form drug manufacturing.

This, in turn, will significantly impact the excipients' demand growth globally. There is a wide scope for industry growth in Europe, including France, Spain, and Italy. This is due to the rising adoption of advanced drugs in these countries. Moreover, regulatory authorities, such as the European Medicines Agency (EMA) and Medicines & Healthcare Products Regulatory Agency (MHRA), are constantly working toward ensuring high safety standards and easy access to low-cost drugs in this region. High disposable income, sophisticated healthcare infrastructure, and a rise in product approvals are expected to create growth opportunities in Europe.

Key players in the market are introducing new products to continuously meet the changing requirements of consumers in the pharmaceutical industry. For instance, in November 2022, Roquette Frères announced the launch of Pearlitol CR-H, enhancing API's sustained release in compression formulations. It further enhances the tableting process giving it a competitive edge.

 Request a free sample copy or view report summary: Sustained Release Excipients Market Report

Sustained Release Excipients Market Report Highlights

• Polymers product segment accounted for the largest share in 2022. Varied usage of polymers in sustained-release formulations is anticipated to fuel industry growth

• Conventional use of the oral delivery route has contributed to the fastest growth of the segment. Convenience, in terms of storage, premeasured doses, portability, and the noninvasive nature of this route are some of the major factors accelerating its adoption

• The rising adoption of transdermal patches has contributed to the fastest growth of the segment

• Targeted drug delivery constituted the largest revenue share in 2022, as a large number of industry players have strong product portfolios. Implantable sustained-release drug delivery systems have improved efficiency, lower adverse effects, and higher convenience, which impels segment growth

• North America dominated the global industry in 2022 owing to the high investments in R&D and the availability of highly sophisticated technologies in the region

• Asia Pacific is projected to register the fastest CAGR during the forecast period due to the growing pharmaceutical industry in emerging countries, such as India and China

• A few of the key market players include Roquette Frères, BASF, International Flavors & Fragrances, Inc., Ashland, Evonik Industries AG, Croda International Plc, and Gattefossé

Sustained Release Excipients Market Segmentation

Grand View Research has segmented the global sustained release excipients market based on product, route of administration, technology, and region:

Sustained Release Excipients Product Outlook (Revenue, USD Million, 2018 - 2030)

• Gelatin

• Polymers

• Minerals

• Sugars

• Alcohol

• Chitosan

Sustained Release Excipients Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

• Oral

• Intramuscular

• Subcutaneous

• Transdermal

• Vaginal

• Ophthalmic

• Intravenous

• Others

Sustained Release Excipients Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted Delivery

• Micro Encapsulation

• Wurster Technique

• Transdermal

• Implants

• Coacervation

• Others

Sustained Release Excipients Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

• Europe

  • U.K.

  • Germany

  • France

  • Spain

  • Italy

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Mexico

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Sustained Release Excipients Market

• BASF

• International Flavors & Fragrances, Inc.

• Ashland Global

• Evonik Industries

• Croda International Plc

• Gattefossé

• Merck KGaA